SCHEMBL4796572

SCHEMBL4796572

COc1ccc2c(C=O)csc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 3/20 0.51
ALDH1A1 P00352 7/20 0.50
MAPT P10636 3/20 0.50
KDM4E B2RXH2 1/20 0.50
ERN1 O75460 3/20 0.49
TRIM24 O15164 1/20 0.49
TYR P14679 1/20 0.49
TRIM33 Q9UPN9 1/20 0.49
PRF1 P14222 1/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2C19 P33261 2/20 0.46
ESR1 P03372 1/20 0.43
PRNP P04156 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
PPARG P37231 1/20 0.40
HTT P42858 1/20 0.40
MAPK10 P53779 1/20 0.40
NCOA2 Q15596 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6152697 0.87 CYP2A6 (0.58) CYP2A6ALDH1A1MAPTKDM4EERN1
SCHEMBL14341668 0.83 PRF1 (0.44) ALDH1A1MAPTKDM4EPRF1CYP1A2
SCHEMBL34459993 0.75 ALDH1A1 (0.44) ALDH1A1MAPTKDM4ECYP1A2CYP2C19
SCHEMBL28633959 0.75 ESR1 (0.49) ALDH1A1MAPTCYP1A2CYP2C19ESR1
SCHEMBL5544081 0.75 ALDH1A1 (0.44) ALDH1A1MAPTKDM4ECYP1A2CYP2C19
SCHEMBL4797361 0.75 ALDH1A1 (0.44) CYP2A6ALDH1A1MAPTKDM4EPRF1
SCHEMBL6811552 0.74 CYP2A6 (0.74) CYP2A6ALDH1A1ERN1PRF1
SCHEMBL1121724 0.74 CYP2A6 (0.56) CYP2A6ALDH1A1MAPTKDM4EERN1
SCHEMBL14599487 0.74 ALDH1A1 (0.42) ALDH1A1MAPTKDM4EPRF1CYP1A2
SCHEMBL30197394 0.74 CYP2A6 (0.74) CYP2A6ALDH1A1ERN1PRF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101133056-B Antitumor compounds NAT HEALTH RESEARCH INSTITUTES 2010-12-01 CN disclosed
US-7456289-B2 Anti-tumor compounds NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2008-11-25 US disclosed
CN-101133056-A Antitumor compounds NAT HEALTH RESEARCH INSTITUTES (CN) 2008-02-27 CN disclosed
EP-1838711-A2 ANTI-TUMOR COMPOUNDS National Health Research Institutes (TW) 2007-10-03 EP disclosed
WO-2006074041-A2 ANTI-TUMOR COMPOUNDS NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2006-07-13 WO disclosed
US-20060148801-A1 Anti-tumor compounds NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148801-A1 Anti-tumor compounds TUBB1, TUBB3, TUBB CYP2A6 4731/4885ALDH1A1 2627/4885MAPT 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.